CAU
ABBV icon

Caxton Associates (UK)’s AbbVie ABBV Stock Holding History

Caxton Associates (UK)’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-4,322
Closed -$802K – 675
2025
Q2 		$802K Sell
4,322
-2,109
-33% -$392K 0.02% 351
2025
Q1 		$1.35M Buy
+6,431
New +$1.25M 0.05% 256

Other funds holding ABBV

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Caxton Associates (UK)'s ABBV Position: Q3 2025 in Review

Caxton Associates (UK) sold out of AbbVie (ABBV) in Q3 2025, closing a stake of 4,322 shares — an estimated $802K sold.

Caxton Associates (UK) first reported a position in ABBV in Q1 2025 and held it in 2 quarters. The position peaked at $1.35M in Q1 2025. 3,906 funds tracked by Wall St. Rank hold ABBV as of Q3 2025.

  • Caxton Associates (UK) reported no remaining AbbVie position as of Q3 2025 after selling out during the quarter.
  • Caxton Associates (UK) sold 4,322 AbbVie shares in Q3 2025, an estimated $802K.
  • Caxton Associates (UK) first reported a position in AbbVie in Q1 2025 and held it in 2 quarters.
  • Caxton Associates (UK)'s AbbVie position peaked at $1.35M in Q1 2025.
  • 3,906 funds tracked by Wall St. Rank held AbbVie as of Q3 2025.

Based on Caxton Associates (UK)'s 13F filing for Q3 2025, filed 17 Nov 2025.